Catalina
Requejo Rodríguez
Publicaciones en las que colabora con Catalina Requejo Rodríguez (9)
2020
-
Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers
Frontiers in Neuroscience, Vol. 14
2019
-
Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation
Neurobiology of Disease, Vol. 121, pp. 252-262
2018
-
Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)
Molecular Neurobiology
-
Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212
-
Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease
Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299
2017
-
Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors
Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735
2015
-
Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration
Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858
2014
-
Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease
International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687
2013
-
In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190